Patients who become HBsAg negative and develop antibody to HBsAg (anti-HBs) are diagnosed as having resolved hepatitis B [3,4]. This is an uncommon phenomenon in chronic HBV infection. During stage HBV DNA may still be detectable by PCR in serum and more often in the liver.

In general, a person is considered very infectious when the test is positive, and less infectious when the test is negative. The loss of e-Antigen can occur naturally or as a result of drug treatment. Sometimes a negative test result can indicate a mutant hepatitis B virus is present.

A hepatitis B vaccine “non-responder” refers to a person who does not develop protective surface antibodies after completing two full series of the hepatitis B vaccine and for whom an acute or chronic hepatitis B infection has been ruled out.

Although HBsAg levels remain unchanged during lamivudine (LMV) treatment, recent studies report an association between a reduction of serum HBsAg level and viral suppression after entecavir (ETV) treatment.

That diet should include:

• Plenty of fruits and vegetables.
• Whole grains such as oats, brown rice, barley, and quinoa.
• Lean protein such as fish, skinless chicken, egg whites, and beans.
• Low-fat or non-fat dairy products.
• Healthy fats like those in nuts, avocados, and olive oil.

Eat foods with protein at each meal: 2 to 3 servings a day of Meat and Alternatives such as lean meat, poultry, fish, eggs, legumes (beans and lentils), tofu, nuts and seeds. 2 to 3 servings a day of Milk and Alternatives such as milk, fortified soy beverage, and yogurt.

Limit foods containing saturated fats including fatty cuts of meat and foods fried in oil. Avoid eating raw or undercooked shellfish (e.g. clams, mussels, oysters, scallops) because they could be contaminated with a bacteria called Vibrio vulnificus, which is very toxic to the liver and could cause a lot of damage.

Coffee consumption had no effect on CAP in people with hepatitis B or C. Based on these findings, the researchers concluded that “coffee consumption is associated with less liver stiffness in patients with NAFLD, HCV and HBV, [and a] trend to less hepatic steatosis in [patients with] NAFLD.”

The estimated carrier life expectancy is 71.8 years, as compared to 76.2 years among noncarriers (Figure ​ 5). These results are consistent with other estimates, which indicate that 15% to 40% of HBV carriers die of liver complications.